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Summary
The biomedical applications of antibody engineering are developing rapidly and have been
expanded to plant expression platforms. In this study, we have generated a novel antibody
molecule in planta for targeted delivery across the blood–brain barrier (BBB). Rabies virus (RABV)
is a neurotropic virus for which there is no effective treatment after entry into the central nervous
system. This study investigated the use of a RABV glycoprotein peptide sequence to assist
delivery of a rabies neutralizing single-chain antibody (ScFv) across an in cellulo model of human
BBB. The 29 amino acid rabies virus peptide (RVG) recognizes the nicotinic acetylcholine receptor
(nAchR) at neuromuscular junctions and the BBB. ScFv and ScFv-RVG fusion proteins were
produced in Nicotiana benthamiana by transient expression. Both molecules were successfully
expressed and purified, but the ScFv expression level was significantly higher than that of ScFv-
RVG fusion. Both ScFv and ScFv-RVG fusion molecules had potent neutralization activity against
RABV in cellulo. The ScFv-RVG fusion demonstrated increased binding to nAchR and entry into
neuronal cells, compared to ScFv alone. Additionally, a human brain endothelial cell line BBB
model was used to demonstrate that plant-produced ScFv-RVGP fusion could translocate across
the cells. This study indicates that the plant-produced ScFv-RVGP fusion protein was able to cross
the in cellulo BBB and neutralize RABV.
Introduction
Rabies remains a major burden in resource-limited countries
particularly in Asia and Africa, accounting for approximately
60 000 deaths per year, mainly in children (Fooks et al., 2014).
The most common source of infection is from an animal bite.
After a period of replication in muscle, the virus gains access to
the peripheral nervous system before entering the central nervous
system (CNS) (Hemachudha et al., 2002) by a process of
retrograde axonal transport. The virus spreads rapidly to the
brain, resulting in an overwhelming encephalitis that kills the host
(Hemachudha et al., 2002; Lewis et al., 2000). Rabies is unique in
that once a productive infection has been established in the CNS,
the outcome is invariably fatal.
Rabies postexposure prophylaxis (PEP) is highly effective if
correctly administered promptly after a potential exposure
(Shantavasinkul and Wilde, 2011; Uwanyiligira et al., 2012).
However, in the case of delayed treatment and the onset of
symptoms, PEP is ineffective. RABV antibodies are unlikely to offer
therapeutic benefits once RABV has entered the CNS as they
cannot cross the blood–brain barrier (BBB) (Pardridge, 2010).
Nicotinic acetylcholine receptors (nAchRs) are ligand-gated
channels located in the neuromuscular junction and in the CNS
(Lentz et al., 1988). nAchRs facilitate RABV entry into both
muscle and neuronal cells (Burrage et al., 1985; Lentz et al.,
1982). The rabies glycoprotein, which forms spikes on the surface
of the virus, contains a short motif which interacts with nAchR to
mediate entry into cells (Lentz, 1990; Lentz et al., 1987). Previous
studies have shown that a linear 29 amino acid peptide derived
from the rabies glycoprotein (RVG) binds to the alpha subunit of
nAchR enabling the delivery of conjugated molecules into the
CNS, including siRNA (Kumar et al., 2007), nanoparticles (Hwang
do et al., 2011; Kim et al., 2013) and enzymes (Fu et al., 2012;
Xiang et al., 2011).
The objective of this study was to engineer a RABV-specific
antibody that was capable of crossing the BBB to neutralize RABV
infection in the CNS. Monoclonal antibody (mAb) 62-71-3 IgG is a
potent rabies neutralizing antibody (Muller et al., 2009). Recom-
binant IgG and single-chain antibody (ScFv) of 62-71-3 was
recently expressed in plants and potent RABV neutralization was
demonstrated (Both et al., 2013). The ScFv was developed further
here to link the RVG peptide using a gene encoding 62-71-3. ScFv
genetically fused with RVG was cloned, expressed in Nicotiana
benthamiana and purified by Ni-affinity chromatography. This
molecule was investigated for RABV neutralization and binding to
nAchR. The results demonstrate that the RVG peptide does not
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affect RABV neutralization, but does facilitate nAchR binding and
transport of the rabies ScFv across an in cellulo BBB model.
Results
Expression of 62-71-3 ScFv and ScFv -RVG fusion
ScFv and ScFv-RVG fusion genes were cloned into the pEAQ
vector (Peyret and Lomonossoff, 2013) as shown in Figure 1, and
the proteins were expressed in N. benthamiana. A time-course of
the protein expression between days 4–7 postinfiltration indi-
cated day 6 was the optimal day to harvest (data not shown). The
expression level of ScFv and ScFv-RVG was approximately 100
and 2 lg/g fresh leaf weight, respectively. The Ni-affinity purified
ScFv fusion and ScFv-RVG fusion were assessed by Coomassie-
stained SDS-PAGE gel (Figure 2a) or by immunoblotting with
anti-E tag antiserum (Figure 2b). The amounts of purified proteins
were quantified by comparing the band intensity with standard
BSA protein (MW 66 kDa). Major bands were observed at the
expected sizes for ScFv and ScFv-RVG fusion of 56 kDa (lane 1)
and 61 kDa (lane 2), respectively. The identity of the bands was
confirmed by Western blot (Figure 2b), which also demonstrated
the presence of higher molecular weight bands (probably
aggregates) and lower molecular weight bands (possibly degra-
dation products). Of note, the ratio of full-length protein over
degraded protein as shown in the immunoblotting (Figure 2b) is
similar for ScFv and ScFv-RVG.
Neutralization of rabies virus
The two versions of 62-71-3 ScFv were tested to determine their
ability to neutralize RABV (ERA strain) in cellulo using a plaque-
inhibition assay. With a starting concentration of 0.5 mg/mL, the
neutralizing activity of ScFv and ScFv-RVG fusion was identical to
the neutralizing activity of 62-71-3 IgG (Figure 3). Statistical
analysis by one-way ANOVA (GraphPad Prism, GraphPad Soft-
ware, Inc. La Jolla, California, USA, version 7.0) confirmed that
there was no significant difference among 62-71-3 IgG, ScFv and
ScFv-RVG neutralizing activities.
Binding to nAchR
Binding and penetration of ScFv and ScFv-RVG fusion of 293 cells
overexpressing nAchR were tested by flow cytometry. A greater
proportion of ScFv-RVG fusion (dotted line) bound to the 293
cells as evidenced by the shift to the right of the dotted line
compared to ScFv (solid line), shown in Figure 4a. A greater
amount of total ScFv-RVG fusion (dotted line) was also found in
the 293 cells overexpressing nAchR compared to ScFv (solid line,
Figure 4b).
UV-inactivated RABV and a-bungarotoxin were used as com-
petitive inhibitors for the interaction between the RVG peptide
and nAchR. Cells pre-incubated with each inhibitor were tested
for their ability to bind and to internalize ScFv and ScFv-RVG
fusion. There was a low-level background entry of ScFv into cells.
This could not be inhibited by pre-incubation with either UV-
Figure 1 Schematic representation of the T-DNA regions of the vectors used in this study (Both et al., 2013). P35S: CaMV 35S promoter, Oryza
sativa leader: O. sativa leader sequence, 62-71-3 VH: variable region of the heavy chain of 62-71-3 monoclonal antibody, L: the (Gly4Ser)3 linker, 62-71-3
VL: variable region of the light chain of 62-71-3 monoclonal antibody, dsRed: red fluorescent protein from Discosoma sp., 29aaRVG: the 29 amino
acid peptide (RVG) from RABV glycoprotein, 6xHis: 6 histidine residues, E: GAPVPYPDPLEPR peptide sequence, the sequences of primers number 1–11
were listed in Table S1.
Figure 2 SDS-PAGE and Western blot analyses of ScFv and ScFv-RVG
fusion proteins. The plant-produced ScFvP (lane 1) and ScFv-RVGP fusion
proteins (lane 2) were purified by Ni-affinity chromatography. ScFv and
ScFv-RVG fusion proteins were analysed by SDS-PAGE under reducing
conditions, followed by (a) staining with Coomassie blue or (b) blotting
onto nitrocellulose and probing with a mouse anti-E tag antiserum. The
expected size of the ScFv and ScFv-RVG fusion is approximately 56 kDa
and 61 kDa, respectively, which are indicated by curly braces.
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inactivated RABV or a-bungarotoxin, indicating that its entry is
mediated by a nonspecific mechanism (Figure 5a and c). In
contrast, the presence of the UV-inactivated virus or a-
bungarotoxin inhibited the entry of ScFv-RVG fusion as evidenced
by the shift to the left of the dotted line compared to the absence
of the competitor (solid line), shown in Figure 5b and d,
respectively. These results confirmed that the entry of ScFv-RVG
fusion protein into cells occurred via a nAchR-mediated pathway.
These experiments were repeated with similar results using a
second cell line, neuroscreen cells (Greene and Tischler, 1976),
which are neuronal cells that express nAchRs (Figure 5e–h).
Passage of ScFv and ScFv-RVG fusion across an in cellulo
model of the blood–brain barrier
The human hCMEC/D3 cell line, which retains morphological and
functional characteristics of brain endothelium, is widely used as a
human in cellulo BBB model (van der Helm et al., 2016). The in
cellulo BBB transport experiment was conducted on the transwell
device made with hCMEC/D3 cell monolayer as described in
Figure 6 (Eigenmann et al., 2013). The barrier integrity of the
human brain endothelial cell monolayer was assessed by trans-
port of the small molecule Lucifer yellow and was determined to
be 2.11 9 103 cm/min, attesting to the tightness of the
junctions (Figure S1, Siflinger-Birnboim et al., 1987). The expres-
sion of nAchR alpha7 on hCMEC/D3 was also confirmed by real-
time PCR (Figure S2). After antibodies were added to the upper
chamber, the medium in the lower chamber was tested for RABV-
neutralizing activity after 2 and 18 h (Figure 6a). These time
points were chosen to eliminate the caveat of BBB alteration after
adding the molecule (i.e. a transport after 2 h only is a very active
transport across the endothelial cell barrier). The full-length 62-
71-3 mAb did not cross the hCMEC/D3 monolayer, consistent
with a previous report for an antibody molecule (Markoutsa
et al., 2011). 62-71-3 IgG-RVG conjugate did not cross the
endothelial cell barrier either (Figure 6b). Some ScFv was found to
cross the hCMEC/D3 cells as the 2 h medium sample had
neutralizing activity (at dilution 1 : 100), but this did not increase
by 18 h (Figure 6b). In contrast, ScFv-RVG fusion passed through
the hCMEC/D3 cells to a much greater extent, and the neutral-
izing activity of the medium in the bottom well increased in a
time-dependent manner (Figure 6b).
In a second assay, UV-inactivated RABV and a-bungarotoxin
were used as competitive inhibitors (Figure 6c). Both are natural
ligands of a7 nAchR. As before, the 62-71-3 IgG-RVG did not
cross the hCMEC/D3 barrier, but the ScFv-RVG fusion did
accumulate in the bottom well in a time-dependent manner.
Pretreating cells with either UV-inactivated RABV or a-bungar-
otoxin reduced the passage of ScFv-RVG fusion at 2 and 18 h,
resulting in at least 10-fold reduction in neutralizing activity found
in the medium in the bottom well (Figure 6d). These inhibitors
had no effect on the transport of 62-71-3 IgG-RVG across the
barrier (Figure 6d).
Discussion
Several strategies for the transport across the BBB by drugs or
antibodies have been proposed, including association with an
antibody recognizing transferrin receptor as a carrier (Friden
et al., 1991; Pardridge, 2015), targeting to the insulin receptor
(Boado et al., 2010; Pardridge et al., 1985) and formulation with
low-density lipoproteins to target the endothelial LDL-receptor
(Alyautdin et al., 1997, 1998; Gulyaev et al., 1999). For plant-
manufactured products, cholera toxin B subunit (CTB) was also
used successfully to deliver proteins accross the BBB (Kohli et al.,
2014; Kwon and Daniell, 2016) or to act as a strong mucosal
adjuvant (Roy et al., 2010; Shahid and Daniell, 2016). Several
proteins were used previously to target drugs to the brain, such as
the human immunodeficiency virus TAT protein (Schwarze et al.,
1999) and RVG peptide (Kumar et al., 2007; Liu et al., 2009). The
RVG peptide constitutes part of the mature rabies viral glycopro-
tein (Kim et al., 2013) that can be visualized as trimeric peplomers
on the surface of the virion and was previously shown to enable
the transvascular delivery of siRNA to the brain (Kumar et al.,
2007). The region of the viral G protein utilized here, as a linear
Figure 3 RABV neutralization of ScFv and ScFv-RVG fusion compared to
61-71-3 IgG. The neutralization assay was performed by the rapid
fluorescent focus inhibition test on BSR cells. The starting concentration of
antibodies was 0.5 mg/mL. Data presented are average values from three
independent experiments, and the error bars indicate the standard
deviation (SD). Statistical significance was determined by one-way ANOVA
(GraphPad Prism, version 7.0).
Figure 4 Binding and penetration of 62-71-3
ScFv to 293 cells overexpressing nAchR by flow
cytometry. Binding (a) and entry (b) were detected
with mouse anti-E antiserum and cy5-conjugated
goat anti-mouse IgG antiserum. Solid line: ScFv,
dotted line: ScFv-RVG fusion protein. The arrows
represent the shift to the right of ScFv-RVG
(dotted line) compared to ScFv (solid line).
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peptide, has a similar amino acid composition to snake venom a-
bungarotoxin (Lentz, 1991), which was previously shown to bind
to nicotinic acetylcholine receptors (nAchR). These receptors are
important as they occur in high density at the neuromuscular
junction, and are present in the central nervous system and on
endothelial cells. Thus, in the case of a-bungarotoxin, these
receptors are also involved in penetration of the toxin into the
brain (Bracci et al., 1988; Donnelly-Roberts and Lentz, 1989;
McQuarrie et al., 1976; Tzartos and Changeux, 1983). Similarly,
the full-length RABV glycoprotein has been shown to interact
with nAchR, allowing virus entry into the brain (Burrage et al.,
1985; Lentz, 1990; Rustici et al., 1989).
Size is a key factor governing the ability of a molecule to pass
the BBB (Jekic, 1979). 62-71-3 ScFv was used in this study
because ScFvs are small molecules that retain the antigen
specificity of the original immunoglobulin (Bird et al., 1988).
The neutralization activity of the plant-produced 62-71-3 ScFv
had previously been confirmed (Both et al., 2013). In this study,
62-71-3 ScFv was produced in N. benthamiana by transient
expression at high yields whereas the ScFv-RVG fusion protein
was expressed at significantly lower levels (Figure 2). Similar
differences in expression levels between the two molecules were
also observed in Escherichia coli (data not shown). Moreover,
there is a degraded product in the purified protein, which is
approximately half the size of the full protein. This degraded
product appeared in the immunoblot, confirming the presence of
the E tag. This fragment might be either the functional ScFv or the
dsRed portion. However, only the band of full-length protein was
used to quantify the amount of molecules used for the next
studies for both ScFv and ScFv-RVG proteins.
Although there are several rabies vaccines and antibodies
developed from plants (Hefferon, 2013; Rosales-Mendoza, 2015;
Shahid and Daniell, 2016), here we show for the first time that a
fusion protein with the RVG peptide can be produced in plants.
Producing the RVG peptide fusion protein in this manner will
remove the conjugation step and potentially reduce production
costs. Both ScFv and ScFv-RVG fusion demonstrated equivalent
neutralization of live RABV in cellulo, indicating that the ability of
ScFv to neutralize the virus was not impaired by fusion to the RVG
peptide.
To test nAchR binding, HEK293 cells overexpressing nAchR
were used (Yamauchi et al., 2011). The ScFv-RVG fusion showed
an increase in binding and penetration to cells overexpressing
nAchR, compared to ScFv. To confirm that the increase in entry
was due to binding to nAchR, both UV-inactivated RABV and a-
bungarotoxin were used independently as competitive inhibitors.
a-bungarotoxin has a similar structure to RVG and binds to nAchR
at the same site as rabies glycoprotein (Donnelly-Roberts and
Lentz, 1989; Lentz, 1991; Lentz et al., 1984, 1987, 1988). This
investigation demonstrated that entry of ScFv-RVG fusion into
nAchR overexpressing cells decreased when the cells were
pretreated with either UV-inactivated RABV or a-bungarotoxin,
confirming the role of RVG peptide in mediating cell entry via the
nAchR.
The BBB possesses specific characteristics that protect the brain
from exposure to both endogenous and exogenous toxins.
However, this protective barrier also limits the delivery of
therapeutic molecules to the brain, a major constraint in devel-
oping suitable tools to neutralize RABV that is replicating in the
CNS. The gold standard for studying transport across the BBB is to
use in vivo animal models, but they are expensive, laborious,
ethically contentious and often lack predictive data. Therefore,
any researcher planning to use animals in their research must first
show why there is no alternative to animal experimentation
(European Commission, directive 201/63/EU) in order to fulfil the
guiding principles underpinning the human use of animals in
scientific research (i.e. the three Rs: Replace, Reduce and Refine).
Previous study suggested that in cellulo models are robust,
reproducible, easy to analyse and allow study of human cells
and tissues (van der Helm et al., 2016) following the 3Rs rules. An
in cellulo model was, therefore, used here to determine, in a first
instance, the potential for the antibodies to cross the human BBB.
Figure 5 Inhibition of binding penetration of
ScFv-RVG fusion into nAchR overexpressing 293
cells and neuroscreen cells by UV-inactivated
RABV and a-bungarotoxin. Flow cytometry on
nAchR overexpressing 293 cells pretreated with
UV-inactivated RABV (a and b) and a-
bungarotoxin (c and d) before incubation with
ScFv (a and c) and ScFv-RVG fusion protein (b and
d). Flow cytometry on neuroscreen cells
pretreated with UV-inactivated RABV (e and f) and
a-bungarotoxin (g and h) before incubation with
ScFv (e and g) and ScFv-RVG fusion protein (f and
h). Solid line: no inhibitor, dotted line: pretreated
with UV-inactivated RABV or a-bungarotoxin. The
arrows represent the shift to the left of ScFv-RVG
(dotted line) compared to ScFv (solid line).
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The hCMEC/D3 cell line has been developed as a model for the
human BBB and has been used to test the permeability of several
drugs (Al-Shehri et al., 2015; Ma et al., 2014). Here, the results
indicated that 62-71-3 ScFv was able to pass across the hCMEC/
D3 cells whilst the 62-71-3 IgG was not. Although the incubation
time was increased from 2 to 18 h, the amount of ScFv crossing
the cells did not increase. This might be due to the ScFv molecule
crossing the cells by passive transport mechanisms and is probably
a reflection of the smaller size of this molecule compared to the
IgG control. However, when the ScFv was fused with the RVG
peptide, the penetration across the cells was significantly
increased (Figure 6b) and occurred in a time-dependent manner
indicating active penetration. When competitive inhibitors, UV-
inactivated RABV and a-bungarotoxin, were used, transport
across the in cellulo BBB decreased for the ScFv-RVG fusion
protein (Figure 6c) suggesting that the ScFv-RVG fusion was
transported across the in cellulo BBB by active transport mech-
anisms involving binding to nAchR.
Although postexposure prophylaxis in rabies is highly effective
when correctly administered, significant challenges remain in
treatment of infection, particularly when patient presentation is
delayed. Alternative approaches to the treatment of late-stage
rabies infection are still urgently required. The data presented
here indicate a potential strategy to deliver potently neutralizing
monoclonal antibody fragments across the BBB and into the CNS.
Additional in vivo animal studies are required to assess pharma-
cokinetics of ScFv linked to RVG and efficacy of this form of
postexposure tool following clinical presentation in an in vivo
model. This approach may lead to a new mechanism by which
postexposure tools can be administered to individuals exhibiting
clinical rabies.
Experimental procedures
Genetic construct design
The 62-71-3 IgG was previously described (Both et al., 2013).
For the cloning of pEAQ-ScFv, primers 1, 2, 3, 4, 5, 6, 7 and 8
were used (Figure 1; for the sequences see Table S1). Primer 1
was designed to introduce the attB recombination sites and the
Oryza sativa signal peptide into the VH domains of mAb 62-71-
3. Primer 2 was used as a reverse primer for linking the VH and
VL domains of mAb 62-71-3 with the (Gly4Ser)3 linker. Primers 3
and 4 were used as forward and reverse primers to amplify VL
domains of mAb 62-71-3 with NotI site at the 3’ end. The VH
and VL domains of mAb 62-71-3 with the (Gly4Ser)3 linker were
linked using overlap PCR using primers 1 and 4. Primers 5 and 6
Figure 6 ScFv-RVG fusion transports across in cellulo BBB model. (a) A schematic diagram of the experiment. 10 lg of antibodies was added to the
upper chamber of hCMEC/D3 cells in the transwell. Medium (collected after 2 or 18 h after adding the molecules) at the bottom of the well was tested
for the presence of RABV-neutralizing antibodies by a RABV neutralization assay. (b) RABV neutralization titre of 62-71-3 IgG, 62-71-3 IgG-RVG
conjugate, ScFv and ScFv-RVG fusion that crossed hCMEC/D3 cells. Each column represents the average values from three independent experiments, and
the error bars indicate for the standard deviation (SD). (c) A schematic diagram of the inhibition experiment. hCMEC/D3 cells were pretreated with either
UV-inactivated RABV or a-bungarotoxin (BT), and then, 10 lg of 62-71-3 IgG-RVG conjugate or ScFv-RVG fusion was added to the upper chamber.
Medium at the bottom of the well was tested for the presence of RABV-neutralizing antibodies by a RABV neutralization assay after 2 and 18 h. (d) RABV
neutralization titre of 62-71-3 IgG-RVG and ScFv-RVG fusion, which crossed hCMEC/D3 cells after the cells were pretreated with or without RABV or BT.
Each column represents the average values from three independent experiments, and the error bars indicate the standard deviation (SD).
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were used as forward and reverse primers, respectively, to
amplify His tag- E tag fusion gene containing NotI and BamHI
sites. Primer 7 was used as a forward primer to amplify dsRed
gene containing BamHI site. Primer 8 was used as a reverse
primer to amplify dsRed and also contained attB recombination
sequence to the 3’ end of dsRed gene. dsRed gene was
included to monitor ScFv/ScFv-RVG expression in cells by
immunofluorescence. The VH and VL domains of mAb 62-71-3
with the (Gly4Ser)3 linker were digested with NotI restriction
enzyme. The fusion His tag - E tag portion was digested with
NotI and BamHI restriction enzymes. The dsRed gene was
digested with BamHI restriction enzyme. These three pieces
were ligated, purified using the QIAquick PCR purification kit
(Qiagen) and recombined into the Gateway entry vector pDONR/
Zeo (all materials for Gateway recombination including enzymes,
entry vector pDONR/Zeo, competent E. coli cells and zeocin,
were obtained from Invitrogen). The E. coli cloning strain DH5a
was heat-shocked with the plasmids and streaked on plates
containing LB plus 50 lg/mL zeocin. Individual colonies were
used for inoculating 5 mL LB medium containing 50 lg/mL
zeocin and were shaken overnight (250 rpm, 37 °C). The
plasmids were purified from a saturated overnight culture with
the QIAprep Spin Miniprep Kit (Qiagen) and used for recombi-
nation with the Gateway destination vector pEAQ-HT-DEST3
(Sainsbury et al., 2009). For the cloning of pEAQ-ScFv-RVG
(Figure 1), the VH and VL domains of mAb 62-71-3 with the
(Gly4Ser)3 linker and the His tag – E tag portion were cloned
using the same method as pEAQ-ScFv. Primers 9 and 10 were
used as forward and reverse primers, respectively, to amplify
RVG peptide with BamHI site at the 5’ end. Primers 11 and 8
were used as forward and reverse primers, respectively, to
amplify dsRed gene. The RVG peptide and dsRed genes were
linked by overlap PCR using primers 8 and 9. After the three
pieces were ligated, the Gateway recombination was performed
using the same method as previously described for pEAQ-ScFv.
Plant inoculation and protein expression
Agrobacterium tumefaciens LBA4404 was transformed with the
pEAQ-ScFv and the pEAQ-ScFv-RVG fusion vectors by electropo-
ration. Recombinant bacterial strains were used to infiltrate leaves
of N. benthamiana plants under vacuum. Leaves were harvested
on days 4, 5, 6 or 7 postinfiltration for expression time-course
experiments. For other experiments, the leaves were harvested on
day 6 postinfiltration. Soluble proteins were extracted in 0.1M
Tris-HCl pH 7.5 + 0.2% Triton X, using a blender before
centrifugation at 18 000g for 10 min. The supernatant was
retained for analysis.
SDS-PAGE and western blot
Plant extracts were denatured by boiling in NuPAGE LDS Sample
Buffer and separated on 4%–12% polyacrylamide gels (Life
Technologies, Warrington, UK). Proteins were either visualized by
Coomassie blue staining or transferred to a nitrocellulose mem-
brane (Amersham Hybond-ECL; Amersham Biosciences, Little
Chalfont, UK). The membrane was blocked with 5% nonfat dried
milk, 0.1% Tween 20 in PBS. The membrane was probed with
horseradish peroxidase (HRP)-conjugated mouse anti-His tag
antiserum (Sigma) or HRP-conjugated mouse anti-E tag antiserum
(Abcam, Cambridge, UK) diluted at 1 : 5000 in 1% nonfat dried
milk in PBST. The membranes were developed by chemi-lumines-
cence using ECL plus detection reagent (GE Healthcare, Buck-
inghamshire, UK).
Protein purification
Plant extract was filtered through Miracloth (EMD Millipore,
Massachusetts, USA), centrifuged at 20 000 g for 15 min and
passed through a 0.2-lm filter (Merck Millipore, Germany).
Purification was by Ni-affinity chromatography with chelating
SepharoseTM (GE healthcare) charged with NiSO4.6H2O. The
antibody molecules were extensively purified from the crude
extract, but this affinity purification method does not reach a
purification at homogeneity.
Cells and viruses
BSR cells (a clone of baby hamster kidney (BHK) cells) were grown
in Dulbecco’s modified Eagle’s medium (DMEM)-Glutamax I (Life
Technologies) supplemented with 10% foetal calf serum and
penicillin/streptomycin. Neuroscreen cells (a subclone of PC12
cells, Cellomics, USA, which express a7-nicotinic acetylcholine
receptor) were grown in RPMI medium (Sigma, Welwyn Garden
City, UK) supplemented with 10% horse serum, 5% foetal calf
serum and penicillin/steptomycin. Human Embryonic Kidney 293
(HEK) cells overexpressing human a7-nicotinic acetylcholine
receptor (nAchR) (Yamauchi et al., 2011) were grown in DMEM
supplemented with 10% foetal calf serum and Pen/Strep. The
nAchR expression in this cell line was monitored by flow
cytometry (data not shown). The hCMEC/D3 cells were grown
in EndoGroTM medium (Millipore, Molsheim, France) according to
the manufacturer’s instruction. The nonpathogenic RABV labo-
ratory strain ERA was propagated as previously described
(Thoulouze et al., 1997).
In cellulo RABV neutralization assay
Neutralization of the ERA strain was performed on BSR cells using
the rapid fluorescent focus inhibition test (Louie et al., 1975). The
negative control consisted of medium without antibody. Dilutions
of the test antibodies were incubated with RABV(<20 PFU) for 1 h
at 37 °C before incubating with BSR cells at 37 °C with 5% CO2.
After 48 h, the supernatant was removed and the cells were fixed
with 80% acetone at 4 °C for 30 min. The cells were washed and
incubated with 1 : 50 FITC-conjugated mouse anti-RABV nucle-
ocapsid antiserum (Bio-Rad, Marnes-la-Coquette, France) at
37 °C for 30 min. After washing, RABV foci were counted using
a fluorescent microscope. Assays were performed in triplicate.
nAchR binding and competition assay
HEK 293 cells expressing human a7-nicotinic acetylcholine
receptor (nAchR) (Yamauchi et al., 2011) or Neuroscreen cells
(entry assay) were seeded on six-well plates. After 24 h, cells
were placed on ice and treated with ScFv preparations for 5 or
30 min, for the binding and entry assays, respectively. Of note,
over a 5-min incubation on ice, it is expected that only a few
single-chain antibody molecules are able to penetrate into the cell
(Lim et al., 2013). After washing, the cells were harvested and
incubated in cell fixation solution (BD Biosciences) for 15 min. For
the binding assay, samples were washed with 1% inactivated
foetal calf serum and 0.1% NaN3 in PBS, pH 7.4, whilst for the
binding-penetration assay, samples were washed with 1%
inactivated foetal calf serum, 0.1% NaN3 and 0.1% saponin in
PBS, pH 7.4, before incubation with 1 : 1000 mouse anti-E tag
antiserum at 4 °C, overnight. The cells were washed and
incubated with goat anti-mouse IgG antiserum conjugated with
cy5 (Jackson laboratory, West Grove, Pennsylvania, USA) at 37 °C
for 1 h. The absence of saponin in the binding assay allowed us to
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detect the ScFv cytoplasmic membrane bound molecule as the
secondary antibody is not able to penetrate inside the cell. Again,
the cells were washed, resuspended in staining buffer and
analysed with FACS CellQuest software (BD, US). Alternatively for
a competition assay, cells were pretreated with either 2x107 PFU
of UV-inactivated RABV’Challenge Virus Strain’ (CVS) (Megret
et al., 2005) (i.e. still able to bind to RABV receptors but not
replicative) or 16 lM a-bungarotoxin (Tocris Bioscience, Bristol,
UK) for 30 min on ice, before the ScFv or ScFv-RVG fusion was
added.
In cellulo BBB transwell assay
The hCMEC/D3 cell line was prepared as described (Eigenmann
et al., 2013) and seeded on the apical side of a Cultrex Rat
Collagen I (150 lg/mL-R&D Systems, Minneapolis, Minnesota,
USA) coated 0.9 cm2 polyethylene terephthalate filter insert with
3.0 lm porosity (BD Falcon, Loughborough, UK). 10 lg of each
antibody preparation was added to the top chamber. The cells
were incubated at 37 °C with 5% CO2, and the medium was
sampled after 2 h and 18 h from the bottom chamber for
neutralizing antibody detection. For inhibition of in cellulo BBB
penetration, UV-inactivated RABV or a-bungarotoxin was added
to the top chamber for 30 min before 62-71-3 IgG-RVG
conjugate and ScFv-RVG fusion protein were added. The medium
in the bottom chamber was sampled as before at 2 h and 18 h.
Determination of the restrictive paracellular
permeability with Lucifer Yellow
The restrictive paracellular permeability of hCMEC/D3 cells was
assessed by their low permeability to the nonpermeant fluores-
cent marker Lucifer Yellow (LY) (Sigma-Aldrich, L0259). Briefly,
after 5 days of culture on filters, hCMEC/D3 monolayers were
transferred to 12-well plates containing 1.5 mL of transport
medium (HBSS CaMg (Gibco, 14025-100) supplemented by
10 mM of hepes (Life technologies, 15630-080) and 1 mM of
sodium pyruvate (Life technologies, 11360)) per well (abluminal
compartment). 0.5 mL transport medium containing 50 lM of LY
was then added to the luminal compartment. Incubations were
performed at 37 °C, 5% CO2 and 95% humidity. After 15, 25
and 45 min, the inserts were transferred into new wells,
beforehand filled with 1.5 mL of transport medium. After
45 min, aliquots were taken for each time point, from both
compartments and the concentration of LY determined using a
fluorescence spectrophotometer (Tecan Infinite F500).
The endothelial permeability coefficient (Pe) of LY was calcu-
lated in centimetres/min (cm/min), as described previously
(Siflinger-Birnboim et al., 1987). To obtain a concentration-
independent transport parameter, the clearance principle was
used. Briefly, the average volume cleared was plotted versus time,
and the slope was estimated by linear regression. Both insert
permeability (PSf, for insert only coated with collagen) and insert
plus endothelial cell permeability (PSt, for insert with collagen and
cells) were taken into consideration, according to the following
formula: 1/PSe=1/PSt1/PSf.
The permeability value for the endothelial monolayer was then
divided by the surface area of the porous membrane of the insert
(Corning, 3460) to obtain the endothelial permeability coefficient
(Pe) of the molecule (in cm/min).
Quantitative polymerase chain reaction
The procedure undertaken has been described in Chopy et al.
(2011). Basically, cDNA synthesis was performed with 1 lg total
RNA using SuperScript II reverse transcriptase (Life Technologies,
France). Quantitative real-time RT-PCR (qRT-PCR) was performed
in triplicate using an ABI Prism 7500 fast sequence detector
system (primers 18S: F: CTT AGA GGG ACA AGT GGC G, R:
ACG CTG AGC CAG TCA GTG TA; a7 AchR QT00074732,
Qiagen, France) with GoTaq PCR master mix (Promega,
Charbonnieres-les-Bains, France). After normalization to 18S
rRNA, the relative abundance of mRNA was obtained by
calculation of the difference in threshold cycles of the test and
control samples (mock value set to 1), commonly known as the
DDCT method.
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